Bilthoven Biologicals in Pandemic Preparedness Contract by European Commission: positive progress

BBio is a fully dedicated vaccine manufacturing company focused on providing affordable vaccines for global health. With its end-to-end vaccine manufacturing based in Bilthoven, the Netherlands, BBio has extensive experience in all aspects of vaccine manufacturing from active substance to finished product, making them a highly suitable partner for this assignment. [iets meer over het proces. Juli vorig jaar gestart, nu positieve audit, klaar in juni 24* nieuwe productie plant en nieuwe filling line]

Sufficient and agile manufacturing

To be prepared for the future, the European Commission established the EU FAB project to ensure EU vaccine manufacturing capacities for future public health emergencies. The objective of the EU FAB project is to ensure that sufficient and agile manufacturing capacities are kept operational during the preparedness phase, which is the period between public health emergencies, to ensure that in the initial phase of a public health emergency sufficient manufacturing capacities are available. Together with other selected companies in Europe, BBio will be part of this network of “ever-warm” vaccine manufacturing facilities, cover all required steps of the manufacturing process up and until batch release, all in the territory of the EU.

Ever warm vaccine facilities

“BBio endorses the importance of having ‘ever-warm’ vaccine manufacturing capacities available in the EU for pandemic preparedness and is highly committed to fulfill its role and responsibility for Europe and global health. This contract with the European Commission will ensure significant supply of viral vector vaccine doses to address potential public health threats,” said Jef de Clercq, CEO at Bilthoven Biologicals.

Long-term EU partner

“Bilthoven Biologicals is proud to be in a position to be a long-term partner for the European Commission for pandemic preparedness. This is a next step in BBio’s continued contribution to public health in Europe and beyond,” said Jorrit van Hoorn, responsible for the Corporate Development at Bilthoven Biologicals.

Partner for viral vaccines

BBio and Batavia Biosciences (Batavia), entered into a collaboration since June 2023 whereby Batavia is manufacturing viral vaccines and viral vectors in a cGMP manufacturing facility (‘Amalia facility’) from BBio. Combining this collaboration with the vaccine manufacturing operations of BBio and the EU Pandemic Preparedness project, BBio shapes itself a future as a partner for viral vaccine and viral vector. “The collaboration with Batavia is an extension of an existing relationship between Bilthoven Biologicals and Batavia and supports the manufacturing of Batavia’s clinical and commercial pipeline. It also shows the ability and flexibility of BBio to partner with other vaccine companies. BBio is uniquely positioned to grow new partnerships based on its broad expertise with viral vaccine manufacturing operations at Utrecht Science Park Bilthoven,” says Van Hoorn.

More about Bbio

BBio is a Netherlands-based end-to-end vaccine manufacturer of viral and bacterial vaccines. The company has a long-standing track record in supplying vaccines to European markets and global health partners such as UNICEF, PAHO and WHO/GAVI. With the manufacturing of polio vaccines, BBio is key contributor to the worldwide program to eradicate polio. BBio is also acting as contract manufacturer of vaccines used as cancer treatment, which is registered and supplied to the European market for the treatment of bladder cancer. BBio covers the entire value chain of vaccine production with its facilities in Bilthoven at the Utrecht Science Park Bilthoven.

Source: Bilthoven Biologicals